ALK-fusion-positive secondary ameloblastic carcinoma reached complete response after using alectinib.
Li S, Li R, Xia J, Zhang Z, Hu L, Zhang S, Sun J, Wang L, Wang L, Huang M, Hao C, Wang B, Li J, Zhang C.
Li S, et al.
Oral Oncol. 2022 Sep;132:105946. doi: 10.1016/j.oraloncology.2022.105946. Epub 2022 Jun 24.
Oral Oncol. 2022.
PMID: 35759857
No abstract available.